News & Updates

Combination treatment with trastuzumab deruxtecan (T-DXd) and radiation therapy (RT) may improve clinical outcomes, without compromising safety, in patients with HER2-positive and HER2-low metastatic breast cancer, reveals a study.

The results from the phase III ROP-ET trial demonstrate the potential of ropeginterferon alfa-2b (ropeg) for the treatment of essential thrombocythaemia (ET) across all risk levels in patients who are ineligible for standard cytoreduction.

Symptoms of overactive bladder (OAC) tend to rise among women receiving both trastuzumab and pertuzumab for HER2-positive positive breast cancer during their treatment, reports a study.

Timely screening is needed to enhance early detection of metabolic health, bone health, and hearing impairment among childhood cancer survivors treated in Singapore, suggests a recent study. Adoption of an exposure-based approach to proactively screen for late effects can reduce biopsychosocial impacts.

New drug applications approved by US FDA as of 16-30 November 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 1-15 November 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A recent study has shown the prevalence of drug-drug interactions (DDIs) among hospitalized patients with haematologic malignancies, with the occurrence increasing alongside the number of medications administered.